Yes-associated protein overexpression in oral squamous cell carcinoma and association with tumor cell migration and invasion

Abstract

Abstract: PURPOSE: To investigate the expression of YAP (Yes-associated protein) in oral squamous cell carcinoma (OSCC) and determine if YAP was associated with tumor cell invasion and migration. METHODS: Sixty-eight primary OSCC patients were enrolled in this study. YAP expression in tissue specimens was investigated by immunohistochemistry staining. YAP putback plasmid with specific mutation sites after YAP-shRNA interference was constructed by site-directed mutagenesis. Cell scratch and cell invasion assay were performed after YAP-siRNA interference or YAP putback again in TB2T4 and SCC23 cells. The data was analyzed using SPSS18.0 software package. RESULTS: Nuclear and cytoplasmic expression of YAP was increased in primary OSCC tissue samples (P<0.05). Nuclear expression of YAP was associated with cervical lymph node metastasis (P<0.001) and 5-year overall survival rate (P=0.008). YAP knockdown greatly suppressed tumor cell migration and cell invasion both in TB2T4 and SCC23 cells (Scramble vs YAP-shRNA, P<0.01), but these abilities were rescued subtotally when YAP was put back to the YAP-shRNA stable cells (Control vs YAP putback, P<0.01). CONCLUSION: YAP expression in OSCC was associated with cervical lymph node metastasis and YAP might play an essential role on the invasion ability of OSCC cells.

Key words: Oral squamous cell carcinoma, Yes-associated protein, immunohistochemistry, RNA interference

CLC Number:

R739.8

ZHOU Rong, SHI Chao-ji, HAN Yong, TAO Wen-jie, LI Jiang, SUN Shu-yang, ZHANG Lei, ZHANG Zhi-yuan. Yes-associated protein overexpression in oral squamous cell carcinoma and association with tumor cell migration and invasion[J]. China Journal of Oral and Maxillofacial Surgery, 2016, 14(3): 203-208.

References

[1] Kademani D. Oral cancer [J]. Mayo Clin Proc, 2007, 82(7): 878-887.
[2] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Can J Clin, 2005, 55(2): 74-108.
[3] Prgomet Z, Axelsson L, Lindberg P, et al. Migration and invasion of oral squamous carcinoma cells is promoted by WNT5A, a regulator of cancer progression [J]. J Oral Pathol Med, 2015, 44 (10): 776-784.
[4] Zhou JP, Gao ZL, Zhou ML, et al. Snail interacts with Id2 in the regulation of TNF-alpha-induced cancer cell invasion and migration in OSCC [J]. Am J Cancer Res, 2015, 5(5): 1680-1691.
[5] Kim NG, Koh E, Chen X, et al. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components [J]. Proc Natl Acad Sci USA, 2011, 108(29): 11930-11935.
[6] Zhao B, Li L, Wang L, et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis [J]. Genes Dev,2012, 26(1): 54-68.
[7] Wada K, Itoga K, Okano T, et al. Hippo pathway regulation by cell morphology and stress fibers [J]. Development, 2011,138(18): 3907-3914.
[8] Dupont S, Morsut L, Aragona M, et al. Role of YAP/TAZ in mechanotransduction [J]. Nature, 2011, 474(7350): 179-183.
[9] Lai ZC, Wei X, Shimizu T, et al. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats [J]. Cell, 2005, 120(5): 675-685.
[10] Harvey K, Tapon N. The Salvador-Warts-Hippo pathway-an emerging tumour-suppressor network [J]. Nat Rev Cancer, 2007, 7(3): 182-191.
[11] Camargo FD, Gokhale S, Johnnidis JB, et al. YAP1 increases organ size and expands undifferentiated progenitor cells [J]. Curr Biol,2007,17(23): 2054-2060.
[12] Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals [J]. Cell, 2007, 130(6): 1120-1133.
[13] Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon [J]. Proc Natl Acad Sci USA,2006,103(33): 12405-12410.
[14] Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma [J]. Cancer, 2009, 115(19): 4576-4585.
[15] Zhang J, Ji JY, Yu M, et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway [J]. Nat Cell Biol, 2009, 11(12): 1444-1450.
[16] Hamaratoglu F, Gajewski K, Sansores-Garcia L, et al. The Hippo tumor-suppressor pathway regulates apical-domain size in parallel to tissue growth [J]. J Cell Sci, 2009, 122(Pt 14): 2351-2359.
[17] Ge L, Smail M, Meng W, et al. Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis [J]. PLoS One, 2011, 6(11): e27529.
[18] Zhang L, Pan HY, Zhong LP, et al. Fos related activator-1 is overexpressed in oral squamous cell carcinoma and associated with tumor lymph node metastasis[J]. J Oral Pathol Med, 2010, 39(6): 470-476.
[19] Sobin LH, Wittekind CH. International Union Against Cancer (UICC). TNM classification of malignant tumours[M]. 6th Ed. New York: Wiley-Liss, 2002.
[20] Zhang L, Ye DX, Pan HY, et al. Yes-associated protein promotes cell proliferation by activating Fos related activator-1 in oral squamous cell carcinoma [J]. Oral Oncol, 2011, 47(8): 693-697.
[21] Huntoon CJ, Nye MD, Geng L, et al. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway [J]. Cancer Res, 2010, 70(21): 8642-8650.
[22] Wang Y, Dong Q, Zhang Q, et al. Overexpression of yesassociated protein contributes to progression and poor prognosis of non-smallcell lung cancer [J]. Cancer Sci, 2010, 101(5): 1279-1285.
[23] Da CL, Xin Y, Zhao J, et al. Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions [J]. World J Gastroenterol, 2009, 15(32): 4055-4061.
[24] Roperch JP, El Ouadrani K, Hendrix A, et al. Netrin-1 induces apoptosis in human cervical tumor cells via the TAp73alpha tumor suppressor [J]. Cancer Res,2008,68(20): 8231-8239.
[25] Tomlins SA, Chinnaiyan AM. Of mice and men: cancer gene discovery using comparative oncogenomics[J]. Cancer Cell, 2006, 10(1): 2-4.
[26] Avruch J, Zhou D, Fitamant J, et al. Mst1/2 signalling toYap: gatekeeper for liver size and tumour development [J]. Br J Cancer, 2011, 104(1): 24-32.
[27] Muramatsu T, Imoto I, Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma [J]. Carcinogenesis, 2011, 32(2): 389-398.
[28] Zhang X, George J, Deb S, et al. The Hippo pathway transcriptional coactivator, YAP, is an ovarian cancer oncogene [J]. Oncogene,2011, 30(25): 2810-2822.
[29] Lamar JM, Stern P, Liu H, et al. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain[J]. Proc Natl Acad Sci USA,2012,109(37): E2441-2450.
[30] Ehsanian R, Brown M, Lu H, et al.YAP dysregulation by phosphorylation or ΔNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets [J]. Oncogene, 2010, 29(46): 6160-6171.